2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Unspecified Adult Solid Tumor, Protocol Specific
1
Resectable Pancreatic Carcinoma
1
Resectable Pancreatic Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Advanced Pancreatic Cancer
1
Adenocarcinoma of the Pancreas
1
Adenocarcinoma
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
30
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Radiotherapy
16
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Nivolumab
13
Ramucirumab
11
Cyclophosphamide
11
Drug Therapy
9
Trastuzumab
8
Erlotinib Hydrochloride
8
zolbetuximab
7
Taxes
7
Radiosurgery
7
trastuzumab deruxtecan
6
cemiplimab
6
Blood Specimen Collection
6
regorafenib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
paricalcitol
×
Clear all
NCT03415854
2026-05-12
NABPLAGEMD
HonorHealth Research Institute
Phase 2
Completed
34 enrolled
11 charts